Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Hims & Hers Health beat revenue estimates in Q3 2025 with $599M, driven by subscriber growth and higher spending, despite missing earnings due to rising costs.

flag Hims & Hers Health reported $599 million in third-quarter 2025 revenue, beating estimates and marking a 49% year-over-year increase, driven by a 21% rise in subscribers to 2.47 million and higher per-user spending. flag Despite missing earnings per share expectations due to increased costs from its shift to compounded drugs and supply chain investments, the company saw strong adjusted EBITDA growth. flag It announced renewed talks with Novo Nordisk to potentially distribute Wegovy and an oral semaglutide version, reversing a June partnership termination. flag The company expects $725 million in GLP-1 revenue by 2026 and reaffirmed its 2030 revenue target of $6.5 billion, citing investments in diagnostics, women’s health, and global expansion. flag Shares rose after hours on the news.

6 Articles